HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proangiogenic effect and showing valuable biomedical application in the proangiogenic therapy. However, the translational potential of HPLW is limited by its low metabolic stability, which would shorten the in vivo efficacy of the molecule. Here, we developed a peptide analog of HPLW, named HPLW2, that retains the structural and biological properties of the original peptide but features an impressive resistance to degradation by human serum proteases. HPLW2 was obtained by covalently modifying the chemical structure of the peptide with molecular tools known to impart protease resistance. Notably, the peptide was cyclized by installing an interstran...
HPLW, a designed VEGF (Vascular Endothelium Growth Factor) receptor-binding peptide, assumes a well ...
Tumor angiogenesis, essential for cancer development, is regulated mainly by vascular endothelial gr...
International audienceAngiogenesis is the development of a novel vascular network from a pre-existin...
HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proang...
The design of efficient vascular endothelial growth factor (VEGF) inhibitors is a high-priority rese...
Angiogenesis is a fundamental process underlining physiological and pathological conditions. It is m...
Vascular Endothelial Growth Factor mimetic peptides have interesting applications in therapeutic ang...
Vascular endothelial growth factor (VEGF) is the main regulator of physiological and pathological an...
Angiogenesis is a fundamental process underlining physiological and pathological conditions. It is m...
The design, structural and biological characterization of a novel VEGF inhibitor peptide is describe...
Vascular endothelial growth factor (VEGF) is the main regulator of physiological and pathological an...
VEGF receptors have been the target of intense research aimed to develop molecules able to inhibit o...
VEGF receptors have been the target of intense research aimed to develop molecules able to inhibit o...
HPLW, a designed VEGF (Vascular Endothelium Growth Factor) receptor-binding peptide, assumes a well ...
Tumor angiogenesis, essential for cancer development, is regulated mainly by vascular endothelial gr...
International audienceAngiogenesis is the development of a novel vascular network from a pre-existin...
HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proang...
The design of efficient vascular endothelial growth factor (VEGF) inhibitors is a high-priority rese...
Angiogenesis is a fundamental process underlining physiological and pathological conditions. It is m...
Vascular Endothelial Growth Factor mimetic peptides have interesting applications in therapeutic ang...
Vascular endothelial growth factor (VEGF) is the main regulator of physiological and pathological an...
Angiogenesis is a fundamental process underlining physiological and pathological conditions. It is m...
The design, structural and biological characterization of a novel VEGF inhibitor peptide is describe...
Vascular endothelial growth factor (VEGF) is the main regulator of physiological and pathological an...
VEGF receptors have been the target of intense research aimed to develop molecules able to inhibit o...
VEGF receptors have been the target of intense research aimed to develop molecules able to inhibit o...
HPLW, a designed VEGF (Vascular Endothelium Growth Factor) receptor-binding peptide, assumes a well ...
Tumor angiogenesis, essential for cancer development, is regulated mainly by vascular endothelial gr...
International audienceAngiogenesis is the development of a novel vascular network from a pre-existin...